Novo Nordisk clinical trials are the talk of the medical community as the 2026 European Congress on Obesity (ECO) approaches. From 12–15 May in Istanbul, Turkey, the pharmaceutical giant will unveil data from 52 different abstracts, marking a pivotal moment for the future of metabolic health. This massive data dump aims to clarify how higher doses of semaglutide and new combination therapies like CagriSema can further push the boundaries of weight management.
The focus of these Novo Nordisk clinical trials extends beyond simple weight loss; the research dives into cardiovascular health, physical function, and the specific needs of women navigating the complexities of menopause.
High-Dose Wegovy® and Oral Innovation
Central to the presentation is the STEP UP trial, which examines a 7.2 mg dose of semaglutide. For patients who plateau on standard dosages, these Novo Nordisk clinical trials suggest that a higher ceiling may provide the necessary metabolic nudge to achieve sustained, long-term results.
Wegovy® (Semaglutide) Pipeline & Real-World Data
| Trial / Study | Dosage | Key Analysis Point | Presentation Timing |
| STEP UP | Semaglutide 7.2 mg | Body Weight Loss & Menopausal Status | Tuesday, 12 May |
| OASIS 4 | Oral Semaglutide 25 mg | Physical Function Improvements | Poster Session |
| ORION | Oral Semaglutide | Comparison vs. Orforglipron | Friday, 15 May |
| SELECT | Semaglutide 2.4 mg | MACE in Menopausal Women | Tuesday, 12 May |
Learn More: Novo Nordisk Announces Significant Price Reduction on Wegovy & Ozempic
AstraZeneca Q3 2026 Results: Total Revenue Rises 7% to $46.9bn as Oncology Leads Growth and FY2026 Guidance Holds
AstraZeneca Q3 2026 results, published 30 October 2026, show nine-month revenue of $46.9bn, up 7% at CER, and Core EPS of $8.00, up 14%. Oncology […]
AbbVie Q3 2026 Results: Skyrizi, Rinvoq and Vraylar Drive $17.404 Billion Revenue as EPS Guidance Rises
AbbVie Q3 2026 Results show $17.404B revenue, led by Skyrizi and Rinvoq, with higher 2026 EPS guidance and a 5.2% dividend increase. […]
Merck Daejeon Bioprocessing Center Opens With €300 Million Investment to Expand Asia-Pacific Biologics Supply
The Merck Daejeon bioprocessing center opened on 29 October 2026 with a €300 million-plus investment, adding cell culture media, process liquids and sterile sampling capacity […]
Next-Generation Therapy: The Impact of CagriSema
The scientific leadership of the company is most evident in the results of the REDEFINE program. These Novo Nordisk clinical trials evaluate CagriSema, a combination of semaglutide and the long-acting amylin analogue, cagrilintide. By targeting multiple satiety pathways simultaneously, CagriSema represents the “next-gen” of obesity treatment.
The scientific leadership of the company is most evident in the results of the REDEFINE program. These Novo Nordisk clinical trials evaluate CagriSema, a combination of semaglutide and the long-acting amylin analogue, cagrilintide. By targeting multiple satiety pathways simultaneously, CagriSema represents the “next-gen” of obesity treatment.
